The Nasdaq-listed healthcare group said it may continue open-market purchases under its existing buyback plan, which authorizes up to $5 million and runs through December 31, 2026.
Cosmos Health Inc. said it repurchased an additional 190,000 common shares in the open market at an average price of about $0.2805 each. That brought total buybacks under its previously announced program to 4,060,000 shares for approximately $811,000, against an authorization of up to $5 million. The company said it intends to keep making open-market repurchases, subject to market conditions, under the plan, which expires on December 31, 2026 and can be renewed at the company’s sole discretion. CEO Greg Siokas said surpassing 4 million shares repurchased reflected management’s view that the stock remains undervalued relative to the company’s fundamentals and long-term potential. Cosmos Health, listed on Nasdaq under COSM, is a diversified, vertically integrated healthcare group with pharmaceutical, nutraceutical, manufacturing, distribution, R&D and telehealth operations across Europe, the UK and the United States.